Brucella lipopolysaccharide monoclonal antibody and cELISA detection kit and detection method based on same

By developing the Brucella lipopolysaccharide monoclonal antibody N1 and cELISA detection methods, the problems of low sensitivity and insufficient specificity in existing brucellosis detection have been solved, enabling rapid, simple and efficient diagnosis of brucellosis.

CN121226541APending Publication Date: 2025-12-30SHANGHAI VETERINARY RESEARCH INSTITUTE CAAS (CHINESE ANIMAL HEALTH & EPIDEMIOLOGY CENTER SHANGHAI BRANCH) +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511386371.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-26
Publication Date
2025-12-30

AI Technical Summary

Technical Problem

Existing methods for detecting brucellosis suffer from low sensitivity and insufficient specificity, are prone to false positives, and are cumbersome to operate, making it difficult to achieve rapid and accurate diagnosis.

Method used

A Brucella lipopolysaccharide monoclonal antibody N1 was developed for a competitive enzyme-linked immunosorbent assay (cELISA) method. By specifically binding to Brucella S-type LPS, it avoids cross-reaction with other pathogens and adopts a one-step mixing incubation strategy, simplifying the operation process.

Benefits of technology

It achieves highly specific and sensitive brucellosis detection, with a detection limit of 1:25600, a 50% reduction in detection time, applicability to multi-host sera, and stable and reliable results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121226541A_ABST
    Figure CN121226541A_ABST
Patent Text Reader

Abstract

The invention relates to a Brucella lipopolysaccharide monoclonal antibody and a cELISA detection kit and detection method based on the same, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region, and is characterized in that the amino acid sequence of the heavy chain variable region is SEQ ID No.1, and the corresponding nucleotide sequence is SEQ ID No.2; the amino acid sequence of the light chain variable region is SEQ ID No.3, and the corresponding nucleotide sequence is SEQ ID No.4. The monoclonal antibody is only specifically combined with smooth LPS of brucella, and has no cross reaction with 21 pathogens such as rough brucella, yersinia O: 9 and the like. The sensitivity of a competitive enzyme-linked immunosorbent assay (cELISA) kit developed on the basis of the antibody reaches 1: 25600 and is improved by 200 times compared with that of a traditional method, the detection time is shortened to 90 min, the in-plate / inter-plate variable coefficient is lower than 9.87%, and the antibody is suitable for high-throughput screening of multi-host serum.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present application relates to the field of biotechnology, in particular to a Brucella lipopolysaccharide (LPS) monoclonal antibody and a competitive enzyme-linked immunosorbent assay (cELISA) detection kit and detection method based on the antibody BACKGROUND

[0002] Brucellosis, caused by Brucella, is a zoonosis with clinical features of animal abortion, infertility, and human long-term fever, sweating, joint pain, etc. It seriously threatens the healthy development of the breeding industry and public health safety. The disease is a class B infectious disease in China, and its purification is of great significance to protect people's life safety and reduce economic losses. Traditional pathogen culture is generally considered the 'gold standard' for microbial identification, but after isolation and culture, biochemical identification, sequencing comparison and analysis, the cycle is long and the efficiency is low, so it is particularly important to establish a rapid and accurate Brucella detection method. At present, the diagnosis methods for Brucella infection mainly include serological and pathogenic methods, and serological diagnosis is most commonly used in the world for brucellosis screening and trade quarantine. The current national standard for the diagnosis of brucellosis in China is GB / T 18646-2018, which includes serological methods such as red plate agglutination test (RBT), tube agglutination test (SAT), complement fixation test (CFT), fluorescence polarization test and enzyme-linked immunosorbent assay (ELISA) etc. Although RBT is simple to operate, its sensitivity is limited, and subjective interpretation has a certain error rate; SAT and CFT have reliable results, but the operation is complicated and time-consuming; fluorescence polarization requires the use of expensive fluorescence polarization analyzers, which limits the promotion of primary institutions; compared with the above methods, ELISA has the advantages of high sensitivity, simple operation and large throughput, among which the ELISA method for detecting Brucella lipopolysaccharide (LPS) antibodies is an effective detection target for determining Brucella infection. However, although indirect ELISA (iELISA) is highly sensitive, it lacks specificity. Due to the structural similarity between LPS and other species of gram-negative bacteria, false positives often occur in test results, such as Yersinia enterocolitica O:9, Salmonella Dublin, Escherichia coli O157, and other pathogens with the same O-polysaccharide epitope have a high cross-reactivity rate. At the same time, iELISA requires enzyme-labeled secondary antibodies from the corresponding source, which is not convenient for detecting different genus sera. The World Organization for Animal Health (WOAH) recommends the use of'screening + diagnosis' strategy for the diagnosis of brucellosis in the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, which uses Rose Bengal Test (RBT) or indirect ELISA (iELISA) for screening and complement fixation test (CFT) or competitive ELISA (cELISA) for diagnosis. This strategy aims to reduce misdiagnosis and is suitable for different epidemiological backgrounds in different regions of the world.Competitive ELISA (cELISA) uses monoclonal antibodies to competitively block antigen-antibody binding; by screening for monoclonal antibodies with high specificity, the aforementioned problems can be circumvented. Brucella lipopolysaccharide (LPS) is a key virulence factor and immunodominant antigen. Screening for monoclonal antibodies targeting the conserved epitope of its O-polysaccharide chain can provide a molecular basis for highly specific diagnosis. Currently, how to obtain highly specific Brucella LPS monoclonal antibodies and establish an efficient, sensitive, and convenient cELISA detection method based on them remains a technical problem that urgently needs to be solved by those skilled in the art. The convenient cELISA developed based on this aims to overcome the limitations of existing detection technologies and provide an accurate and rapid diagnostic tool for brucellosis prevention and control. Summary of the Invention

[0003] To overcome the shortcomings of existing technologies, the present invention aims to provide a Brucella lipopolysaccharide monoclonal antibody and a cELISA detection kit and method based on it. This antibody exhibits high specificity, and the detection kit and method based on this antibody are highly sensitive, easy to operate, and rapid, effectively addressing the deficiencies of existing detection methods. The objective of this invention is achieved through the following technical solution:

[0004] In a first aspect, this invention provides a Brucella LPS monoclonal antibody N1, comprising a heavy chain variable region and a light chain variable region. The amino acid sequence of the heavy chain variable region is SEQ ID No. 1, and the corresponding nucleotide sequence is SEQ ID No. 2. The amino acid sequence of the light chain variable region is SEQ ID No. 3, and the corresponding nucleotide sequence is SEQ ID No. 4. This monoclonal antibody has the following characteristics: it specifically binds only to the smooth (S-type) lipopolysaccharide (LPS) of Brucella, and does not cross-react with 21 other pathogens or recombinant proteins, including Brucella roughi, Yersinia O:9, Salmonella Dublin, Escherichia coli O157:H7, Brucella BP26, and Mycobacterium tuberculosis IFN-γ. Furthermore, the binding site of this antibody to LPS is not the same as that of positive sera from 10 common pathogens, including Brucella roughi, Yersinia O:9, Salmonella Dublin, and Escherichia coli O157:H7, effectively eliminating false positives during serum competitive incubation.

[0005] Secondly, a cELISA detection kit based on the aforementioned Brucella LPS monoclonal antibody is provided. The kit includes: 1. Coating antigen: Brucella lipopolysaccharide (LPS), concentration 0.2 μg / mL; 2. Detection antibody: Horseradish peroxidase (HRP)-labeled N1 monoclonal antibody, diluted 1:100 before use; 3. Reaction buffer: including carbonate buffer (for coating), PBST washing buffer (PBS containing 0.05% Tween-20), and 5% skim milk blocking buffer; 4. Colorimetric system: TMB substrate solution, 2M H2SO4 stop solution; 5. Controls: positive control is Brucella positive serum, negative control is healthy animal serum; 6. Other auxiliary reagents: 96-well microplate, pipette tips, reaction tubes, etc.

[0006] Thirdly, a method for detecting Brucella using the above-mentioned kit is provided. This method utilizes competitive enzyme-linked immunosorbent assay (ELISA) to determine the presence of Brucella antibodies in the sample based on the inhibition rate. Specifically, the method includes the following steps: 1. Coating: Dilute Brucella LPS to 0.2 μg / mL with carbonate buffer, add 100 μL to each well of a 96-well ELISA plate; incubate at 4°C for 12 h, discard the coating solution, wash three times with PBST washing buffer for 30 s each time, and pat dry. 2. Blocking: Add 200 μL of 5% skim milk blocking buffer to each well, incubate at 37°C for 1 h; discard the blocking solution, wash three times with PBST washing buffer for 30 s each time, and pat dry. 3. Reaction: Dilute the serum to be tested with 0.5% BSA solution at a ratio of 1:10, and simultaneously dilute the HRP-labeled N1 monoclonal antibody with 0.5% BSA at a ratio of 1:100. Mix the diluted serum to be tested with an equal volume of HRP-labeled N1 monoclonal antibody, adding 100 μL of the mixture to each well. Set up positive, negative, and blank controls. The positive and negative controls are treated the same as the serum to be tested, while the blank control is replaced with 5% skim milk. Incubate at 37°C for 30 min, discard the reaction solution, wash three times with PBST washing buffer for 30 s each time, and pat dry. 4. Color Development and Termination: Add 100 μL of TMB substrate solution to each well and incubate at 37°C in the dark for 30 min. Add 50 μL of 2M H2SO4 stop solution to each well, gently vortex to mix, and measure the absorbance (OD value) at 450 nm using a microplate reader within 10 min. 5. Result Interpretation: Calculate the inhibition rate (PI): PI = [(OD negative control - OD test sample) / OD negative control] × 100%; when PI ≥ 29.94%, it is judged as positive; when PI < 29.94%, it is judged as negative.

[0007] Overall, the present invention has the following advantages:

[0008] 1. High Specificity: Brucella LPS monoclonal antibody N1 recognizes only the conserved epitope of Brucella S-type LPS and shows no cross-reactivity with 19 pathogens, including Yersinia enterocolitica O:9 and Salmonella Dublin, and 2 recombinant proteins. This includes 4 common cross-reactive pathogens: Brucella roughy, Yersinia enterocolitica O:9, Salmonella Dublin, and Escherichia coli O157:H7. It precisely targets the binding site on Brucella LPS. Furthermore, in competitive assays with 10 positive sera, including the 4 common cross-reactive pathogens mentioned above, clonal antibody N1 also binds efficiently to the coated LPS antigen, effectively avoiding all other cross-reactivity between sera and LPS during the colorimetric process, resulting in highly accurate detection results.

[0009] 2. High sensitivity: The detection limit can reach 1:25600, which is 200 times higher than the traditional red tiger plate agglutination test (1:128), and can accurately detect weak positive samples.

[0010] 3. Simple and fast operation: The one-step mixed incubation strategy is adopted to react serum samples with HRP-labeled N1 monoclonal antibody simultaneously, shortening the detection process to about 90 minutes, which is 50% faster than the traditional multi-step ELISA.

[0011] 4. High versatility: No species-specific secondary antibody is required, enabling simultaneous detection of serum from multiple hosts such as cattle, sheep, mice, and rabbits, making it suitable for large-scale epidemiological surveillance.

[0012] 5. Good stability: Repeatability tests show that the intra-plate coefficient of variation (CV) is 1.85%-6.08% and the inter-plate coefficient of variation is 1.9%-9.87%, and the test results are stable and reliable. Attached Figure Description

[0013] Figure 1 The schematic diagram of the cELISA detection method shows the process of LPS coating, competitive binding of antibodies in the serum to be tested with HRP-labeled N1 monoclonal antibodies to LPS, and the colorimetric reaction.

[0014] Figure 2 The identification results of lipopolysaccharide (LPS), among which, Figure 2 A: SDS-PAGE image of extracted LPS (lane 1 is extracted LPS; lane 2 is blank control). No protein bands were observed after Coomassie Brilliant Blue staining, indicating good purity. Figure 2 B: Western blot diagram of extracted LPS (lane 1 is extracted LPS; lane 2 is blank control), showing that LPS can react with Brucella positive serum. Figure 2C: Silver staining pattern of extracted LPS (lane 1: 40 μg LPS; lane 2: 20 μg LPS; lane 3: 10 μg LPS), showing typical polysaccharide-specific ladder-like bands.

[0015] Figure 3 iELISA method was used to compare the reactivity of N1, N4, and N5 monoclonal antibodies to LPS. The ordinate represents OD. 450 The N1 serum showed the highest reactivity (P<0.001), where P represents the positive control serum from mice.

[0016] Figure 4 Purification and competitive assay results of monoclonal antibodies. Figure 4 A: SDS-PAGE image (lane1-lane3 are mouse ascites fluid of monoclonal antibodies N1, N4, and N5, respectively; lane4 is the negative control; lane5-7 are purified monoclonal antibodies N1, N4, and N5, respectively). The heavy chain is about 50 kDa, the light chain is about 25 kDa, and there are no other proteins. Figure 4 B: In the monoclonal antibody competition test of N1, N4 and N5, N1 had the highest average inhibition rate.

[0017] Figure 5 Schematic diagram of recombinant monoclonal antibody expression and verification results. Figure 5 A: Schematic diagram of antibody structure, including variable and constant regions of heavy and light chains. Figure 5 B: Schematic diagram of recombinant antibody expression based on HEK293T cells. Figure 5 C: iELISA results of eukaryotic expression antibody supernatant. The cell supernatant transfected with recombinant plasmid was still positive after 8-fold dilution, while the empty vector control group was negative. Figure 5 D: Western blot of recombinant antibody (Lane 1 is cell supernatant of recombinant antibody; Lane 2 is cell supernatant transfected with empty pcDNA3.1(+)). Recombinant antibody can react with LPS.

[0018] Figure 6 Optimal cELISA test conditions for screening positive serum. Figure 6 A: The iELISA titers of the 6 positive sera were as follows: P1-P6, with OD values ​​of 0.815, 0.158, 0.864, 0.304, 0.882, and 0.363, respectively. The average value of the negative control was 0.073. P4 and P6 had the lowest OD values ​​and were defined as weakly positive. Figure 6 B: Average PI value at different LPS coating concentrations, with the highest value at 0.2 μg / mL. Figure 6 C: Optimized results of serum dilution ratio and enzyme-labeled monoclonal antibody dilution ratio, with 1:10 and 1:100 yielding the best results. Figure 6D: The incubation and color development times were optimized, and the average inhibition rate was highest at 30 min.

[0019] Figure 7 ROC analysis of cELISA Figure 7 A: The interactive dot plot displays the serum PI value, with the cutoff value set at 29.94%. Figure 7 B: ROC curve, AUC = 0.9952 (95% CI: 0.9890–1.000), indicating excellent diagnostic efficacy.

[0020] Figure 8 Experimental analysis of sensitivity and specificity, Figure 8 A: A comparison of the sensitivity of RBT, cELISA and iELISA shows that cELISA can reach 1:25600. Figure 8 B: The specific test results of cELISA showed no cross-reactivity with positive sera from 10 other pathogens. Figure 8 C: The specific test results of iELISA show cross-reactivity with some pathogens. Detailed Implementation

[0021] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. The test materials used in the embodiments of the present invention, unless otherwise specified, are all conventional test materials in the art and can be purchased through commercial channels. Experimental methods in the following embodiments that do not specify specific conditions are performed according to conventional methods and conditions, or according to the product instructions.

[0022] The following examples involved the following: SP2 / 0 myeloma cells and Balb / c mice were purchased from Shanghai Slack Laboratory Animal Co., Ltd.; LAtaq enzyme and PCR buffer were purchased from Takara; HRP labeling kit was purchased from Shanghai Sangon Biotech Co., Ltd.; TMB substrate solution and 2MH2SO4 solution were purchased from Jiangsu Tianjingsha Gene Detection Co., Ltd.; 96-well microplates were purchased from Corning; and microplate readers were purchased from Thermo Fisher Scientific.

[0023] Brucella S2, Escherichia coli O157:H7, Yersinia O:9, Salmonella Dublin and other strains were provided by the Food Safety Team of the Shanghai Veterinary Research Institute of the Chinese Academy of Agricultural Sciences.

[0024] Example 1: Preparation of serum and bacterial strain samples

[0025] 1. Preparation of serum samples: From June 2023 to December 2024, a total of 5201 Brucella bovine serum samples were collected from 7 provinces and cities in China. These samples were initially screened using red blood cell antigen and a commercial iELISA kit, resulting in 240 positive samples (Table 1). In addition, one positive and one negative serum sample from mice and rabbits were prepared, along with one polyclonal antibody serum each for Salmonella Dublin, Yersinia enterocolitica, Escherichia coli O157:H7, and Brucella brucellosis. Positive sera for Haemophilus paragallinarum, Lawsonia intracellularis, Escherichia coli O2 serotype, Echinococcosis, Cryptosporidium, and Trichinella spiralis were used as specificity verification sera (Table 1).

[0026] Table 1. Description of serum samples used in this study

[0027]

[0028]

[0029] 2. Preparation of bacterial strain samples: The bacteria used in this study are shown in the table below, in order to better express the monoclonal antibody, determine the extent of any cross-reactivity of the monoclonal antibody with other bacteria, and prepare positive sera.

[0030] Table 2. Bacterial strains and proteins used in this study.

[0031]

[0032] Example 2: Extraction and Validation of Brucella LPS

[0033] 1. LPS Extraction: Brucella lipopolysaccharide (LPS) was extracted using the hot phenol method. The specific experimental method is as follows: Approximately 50g of Brucella wet weight (5g dry weight) was suspended in 170mL of distilled water, heated to 66℃, and an equal volume of phenol solution preheated to 66℃ was added. The mixture was stirred continuously at 66℃ for 15min, cooled to 4℃, and centrifuged at 10000×g for 15min at 4℃. The lower phenol phase was aspirated with a long needle, filtered through filter paper to remove cell debris, and 500mL of cold methanol solution containing 1% saturated sodium acetate was added (500mL methanol + 5mL saturated sodium acetate). Sodium acetate-methanol solution was used to precipitate the precipitate at 4°C for 2 hours, followed by centrifugation at 10000×g for 10 minutes. The precipitate was then resuspended in 80 mL of sterile deionized water, stirred at 4°C for 18 hours, centrifuged at 10000×g for 10 minutes, and the supernatant was collected and stored at 4°C. Another 80 mL of sterile deionized water was added to the precipitate, and the mixture was stirred at 4°C for 2 hours, centrifuged at 10000×g for 10 minutes, and the supernatant was collected. The two supernatants were mixed, and three volumes of a 1% saturated sodium acetate-methanol solution were added. The mixture was precipitated at 4°C for 2 hours, centrifuged at 10000×g for 10 minutes, and then air-dried. The precipitate was resuspended in 50 mL of sterile deionized water, and DNA and RNase were added to a concentration of 0.01 mg / mL. The mixture was incubated at 37°C for 30 minutes, and proteinase K solution was added to a concentration of 0.15 mg / mL. The mixture was incubated at 55°C for 3 hours, then overnight at room temperature. The mixture was centrifuged at 30000 rpm for 3 hours, and the precipitate was collected and dissolved in sterile deionized water at a concentration of 1 mg / mL for later use.

[0034] 2. LPS Validation: Two SDS-PAGE gels were prepared. Dissolved LPS was subjected to SDS-PAGE electrophoresis. Protein marker, LPS, and PBS were added to the three lanes, respectively. One gel was stained with Coomassie Brilliant Blue, destained, and then observed. The other gel was transferred to a membrane, incubated with Brucella rabbit positive serum, and validated using rabbit secondary antibody via Western blotting. In the LPS silver staining identification assay, 40 μg, 20 μg, and 10 μg of LPS sample were added to the SDS-PAGE gel, respectively, for electrophoresis, followed by silver staining identification.

[0035] Example 3: Preparation and Characterization of Brucella LPS Monoclonal Antibody

[0036] 1. Animal immunization: Balb / c mice were immunized with whole Brucella bacteria every 10 days for a total of 3 times. After the third immunization, the titer of the immune serum was detected by iELISA using an LPS-coated ELISA plate, and mice with high titers were selected. Selected mice were given a booster immunization by intraperitoneal injection of whole Brucella bacteria. The mice were sacrificed 3 days later and spleen cells were collected.

[0037] 2. Hybridoma cell preparation: SP2 / 0 myeloma cells were fused with spleen cells using polyethylene glycol (PEG) at a ratio of 2:3. The fused cells were seeded in DMEM medium containing 20% ​​fetal bovine serum and 1× hypoxanthine-aminopterin-thymidine (HAT) and cultured in a 5% CO2 incubator at 37°C. After 10-12 days of culture, the supernatant of the fused cells was screened by iELISA, and positive wells were labeled with LPS as the coating antigen.

[0038] 3. Subcloning and Ascites Preparation: Hybridoma cells from positive wells were subcloned three times using a limiting dilution method to obtain single hybridoma cell lines; the expanded hybridoma cells (2.5 × 10⁻⁶) were then... 6 (1 cell) was injected intraperitoneally into Balb / c mice that had been pretreated with liquid paraffin; 10 days later, the ascites fluid of the mice was collected, centrifuged at 12000×g for 10 min at 4℃, and the supernatant was collected and stored at -20℃.

[0039] 4. Monoclonal antibody purification and identification: Ascites fluid was purified using a Protein G affinity chromatography column. The resin was pre-washed and equilibrated with 20 column volumes of binding buffer (20 mM sodium phosphate buffer, pH 7.0). After loading the sample, non-specific binding was washed away with binding buffer, followed by elution with 0.1 M glycine buffer (pH 2.7). The purified protein was immediately neutralized with one-fifth volume of 1 M Tris-HCl solution (pH 9.0). The purified protein was subjected to SDS-PAGE assay, which showed that the purified antibody heavy chain was approximately 50 kDa, the light chain was approximately 25 kDa, and no contaminating proteins were found. The monoclonal antibody was identified as IgG3κ type using a commercial mouse monoclonal antibody subtype ELISA kit (SBA Clonotyping System-HRP).

[0040] 5. Characterization of Monoclonal Antibodies: The reactivity of ascites fluid containing three monoclonal antibodies (N1, N4, N5) to Brucella LPS was detected by iELISA, with mouse Brucella-positive serum used as a positive control. The results are as follows: Figure 3 As shown, the valences of N1, N3, and N5 reached 8.192 × 10⁻⁶. 5 5.12×10 4 6.4×10 3N1 showed the highest reactivity (P<0.001). Specificity assays for the monoclonal antibodies were performed using iELISA. The tested bacterial strains are shown in Table 2. The results showed that antibodies N1 and N4 only bound to wells coated with LPS and whole-cell Brucella sclerotium (Table 2), exhibiting extremely high specificity. Antibody N5 not only bound to wells coated with LPS and whole-cell Brucella sclerotium, but also reacted with Brucella rubra var. roughiflora, indicating that this monoclonal antibody can detect all Brucella species, including Brucella rubra var. roughiflora. None of the three monoclonal antibodies reacted with any other bacterial strains. cELISA was performed using one positive and one negative serum sample from cattle (cow-P / N), sheep (goat-P / N), mice (mouse-P / N), and rabbits (rabbit-P / N) to assess the competitive binding ability of the three monoclonal antibodies to LPS. The results showed that all four Brucella positive sera effectively interfered with the binding of N1, N4, and N5 to LPS. Even the sheep serum, which had the lowest inhibition rate, showed a significant difference in PI value compared to the corresponding negative serum (P = 0.0124). The average inhibition rates of the three monoclonal antibodies were 81.64%, 81.19%, and 80.27%, respectively. Figure 4 Therefore, N1, which has the highest average inhibition rate, was selected as the detection antibody for subsequent cELISA development.

[0041] Table 3. Reactivity of lipopolysaccharide monoclonal antibodies with bacterial strains and proteins.

[0042]

[0043] Example 4: Sequencing of monoclonal antibodies and verification of recombinant antibody expression

[0044] 1. Total RNA Extraction and cDNA Synthesis: N1 hybridoma cell lines were used, and total RNA was extracted using Trizol reagent (Invitrogen, USA) according to the kit instructions. After RNA extraction, the RNA concentration and purity were determined using a UV spectrophotometer (OD260 / OD280 should be between 1.8 and 2.0). RNA was reverse transcribed into cDNA using SuperScript III reverse transcriptase (Invitrogen, USA). The reaction mixture consisted of: 5 μg total RNA, 1 μL Oligo(dT)18 primer, 1 μL dNTP mixture (10 mM), and RNase-free water to a final volume of 12 μL. The mixture was incubated at 65°C for 5 min, followed by an ice bath for 2 min. Then, 4 μL of 5× reverse transcription buffer, 1 μL of 0.1 M DTT, 1 μL of RNase inhibitor, and 1 μL of SuperScript III reverse transcriptase were added, bringing the total reaction volume to 20 μL. The mixture was incubated at 42°C for 50 min, and the reaction was terminated by heating at 70°C for 15 min. The cDNA was stored at -20°C.

[0045] 2. Variable Region Gene Amplification and Sequencing: Specific primers (Eurofins Genomics) were designed based on the conserved sequences of the IgG3 heavy chain and κ light chain. The heavy chain primer was IgG3-RT (5'-TCATTTACCAGGGGAGCGAGA-3'), and the light chain primer was Igkappa-RT (5'-CTAACACTCATTCCTGTTGA-3'). The PCR reaction system consisted of: 2 μL cDNA template, 5 μL 10×PCR buffer, 4 μL dNTP mixture (2.5 mM), 1 μL upper primer (10 μM), 1 μL lower primer (10 μM), 0.5 μL Taq DNA polymerase (5 U / μL), and sterile water to a final volume of 50 μL. Reaction conditions: 95℃ pre-denaturation for 5 min; 95℃ denaturation for 30 s, 58℃ annealing for 30 s, 72℃ extension for 45 s, for a total of 35 cycles; final extension at 72℃ for 10 min. The PCR products were identified by 1.5% agarose gel electrophoresis. The target fragment (approximately 350 bp of heavy chain variable region and approximately 320 bp of light chain variable region) was recovered, ligated into the pMD19-T vector (Takara, Japan), transformed into E. coli DH5α competent cells, and positive clones were selected for sequencing (Shanghai Sangon Biotech Co., Ltd.).

[0046] 3. Construction of Recombinant Antibody Expression Vectors: The heavy and light chain variable region genes, verified by sequencing, were cloned into the eukaryotic expression plasmid pcDNA3.1(+) (Invitrogen, USA) to construct the recombinant expression vectors pcDNA3.1-IGH and pcDNA3.1-IGK. Specific steps: The target gene and the pcDNA3.1(+) vector were double-digested with restriction endonucleases (EcoRI and XhoI), and incubated at 37°C for 3 h. The digestion products were recovered by agarose gel electrophoresis and ligated overnight at 16°C using T4 DNA ligase (Takara, Japan). The ligation products were transformed into *E. coli* DH5α competent cells, plated on LB agar plates containing ampicillin (100 μg / mL), and cultured at 37°C for 12-16 h. Single colonies were picked, and plasmids were extracted for restriction enzyme digestion identification and sequencing verification to ensure correct insertion of the target gene into the vector.

[0047] 4. Expression and Validation of Recombinant Antibody in HEK293T Cells: HEK293T cells were seeded in 6-well plates and cultured until confluence reached 70%-80%. pcDNA3.1-IGH and pcDNA3.1-IGK (mass ratio 1:1) were co-transfected using a calcium phosphate transfection kit (Beyotime, China). A negative control group transfected with empty vector pcDNA3.1(+) was also included. 48 h after transfection, cell supernatant was collected, and the titer of the recombinant antibody was detected by iELISA. The results showed that the cell supernatant transfected with the recombinant plasmid remained positive (OD450>0.3) even after an 8-fold dilution, while the empty vector control group was negative (OD450<0.1). Figure 5 As shown in C. Western blot verification: LPS was subjected to SDS-PAGE electrophoresis and then transferred to a membrane, blocked with 5% skim milk for 1 h; cell supernatant (1:100 dilution) was added, and incubated overnight at 4°C; after washing with PBST, HRP-labeled goat anti-mouse IgG (1:5000 dilution) was added, and incubated at 37°C for 1 h; ECL staining showed that the recombinant antibody could specifically bind to LPS, showing the expected band, while the empty vector control group showed no band, as shown in Figure C. Figure 5 As shown in D.

[0048] Example 5: Optimization of experimental conditions for the cELISA detection kit

[0049] I. Determination of reagent kit composition:

[0050] 1. Coating antigen: Brucella LPS extracted and verified by the hot phenol method, with the concentration adjusted to 0.2 μg / mL, aliquoted and stored at -20℃.

[0051] 2. Antibody detection: The purified N1 monoclonal antibody was labeled using an HRP labeling kit (Sangon Biotech, China) according to the instructions. After preparation, the antibody was aliquoted and stored at -20℃. It was diluted 1:100 before use.

[0052] 3. Reaction buffer: Carbonate buffer (0.05M, pH 9.6) for LPS coating; PBST washing buffer (0.01M PBS containing 0.05% Tween-20, pH 7.4); 5% skim milk blocking buffer (prepared with PBST).

[0053] 4. Controls: Positive control was Brucella positive rabbit serum (titer 1:202400), and negative control was healthy rabbit serum. Both were sterilized and aliquoted, and stored at -20℃.

[0054] 5. Other reagents: TMB substrate solution (store away from light), 2M H2SO4 stop solution, 96-well microplate (Corning, USA), sterile pipette tips (10μL, 100μL, 1000μL), serum dilution plate, etc.

[0055] II. Optimization of testing conditions:

[0056] 1. LPS Coating Concentration Optimization: LPS was diluted to 0.01, 0.05, 0.1, 0.2, 0.3, 0.5, 1, 2, and 5 μg / mL, respectively, and coated 96-well plates. Each concentration was replicated in triplicate. Six positive sera (P1-P6) and one negative sera were used for cELISA detection, and the average inhibition rate (PI) was calculated. The results showed that the average PI value was highest at 0.2 μg / mL (72.96%), therefore this concentration was selected as the optimal coating concentration.

[0057] 2. Optimization of serum and enzyme-labeled monoclonal antibody dilution ratios: Positive serum was diluted at 1:10, 1:20, 1:40, 1:80, 1:160, and 1:320, while HRP-N1 was diluted at 1:100, 1:200, 1:400, 1:800, 1:1600, and 1:3200. These ratios were then analyzed using a checkerboard titration method, with the combination showing the highest PI value being the optimal one. Results showed that a serum dilution ratio of 1:10 and an HRP-N1 dilution ratio of 1:100 yielded the highest PI value (85.23%), and this ratio was determined to be the optimal one.

[0058] 3. Incubation time optimization: The incubation time for the serum and HRP-N1 mixture was set to 30, 60, and 120 min, and the color development time was set to 15 and 30 min, with three replicates for each condition. The results showed that the PI value difference between positive and negative serum was most significant when the incubation time was 30 min and the color development time was 30 min (P<0.01), so this condition was selected.

[0059] Table 4 Optimized conditions for N1 antigen ELISA

[0060]

[0061] Example 6: Determination of Critical Values

[0062] The cutoff value, sensitivity, and specificity of cELISA were determined using 168 positive sera and 301 negative sera initially screened by RBT and iELISA. The percentage of inhibition for each sample was calculated and displayed in an interactive dot plot. Figure 7 A). In addition, ROC analysis was performed to determine the cutoff value for this detection method at appropriate diagnostic sensitivity and specificity. Figure 7(B) According to ROC analysis, the area under the curve (AUC) was determined to be 0.9952 (95% confidence interval: 0.9890–1.000). Notably, when the cutoff value of the developed cELISA was set at 29.94%, the Youden index was 196.55, the maximum value, at which point the diagnostic sensitivity and specificity were 99.34% (95% confidence interval: 97.61%–99.88%) and 98.21% (95% confidence interval: 94.88% to 99.51%), respectively. Therefore, the cutoff value for PI was determined to be 29.94%, with serum samples having a PI < 29.94% considered negative, and those having a PI ≥ 29.94% classified as positive.

[0063] Example 7: Sensitivity, Specificity, and Repeatability Validation

[0064] The sensitivity of the detection methods was verified by RBT, iELISA and cELISA respectively. The results showed that iELISA had the highest detection sensitivity and could still effectively detect rabbit polyantiserum diluted 1:204800. cELISA was the second most effective, reaching 1:25600, while red erythromycin had the worst sensitivity, reaching only 1:128.

[0065] iELISA and cELISA were used to verify the specificity of the detection method. The results showed that the PI values ​​of positive sera for the seven other pathogens in the cELISA detection method were all below 20%, indicating that the cELISA detection method of this invention has good specificity. However, due to LPS being used as the detection antigen, iELISA showed positive results for Brucella brucellosis, Salmonella Dublin, Escherichia coli O157H:7, and Yersinia enterocolitica. Figure 8 B. Figure 8 C). Compared with a commercially available cELISA kit of the same type (Keqian Biotechnology, catalog number: 885014, veterinary drug production license number 170048118), the test revealed that the commercial kit had severe cross-reactivity with positive serum of Yersinia enterocolitica from sheep (Table 6).

[0066] Table 5. Results of sheep-specific serum detection using the Keqian Bio cELISA kit.

[0067]

[0068] Repeatability and reproducibility results showed that the intra-assay CV of PI was 1.85% to 6.08%, and the inter-assay CV was 1.9% to 9.87%, indicating that the cELISA of the present invention has good repeatability and reproducibility (Table 77).

[0069] Table 6. Stability analysis of cELISA (intra- and inter-plate repeatability)

[0070]

[0071] Example 8: Clinical detection performance of cELISA and comparison with commercial kits

[0072] The cELISA method developed in this study, the commercially available iELISA kit, and the cELISA kit were used to detect 72 Brucella-positive serum samples and 131 Brucella-negative serum samples in the test set.

[0073] The results showed that RBT detected 29 positive serum samples and 174 negative serum samples; cELISA detected 73 positive serum samples and 130 negative serum samples; the commercial iELISA kit identified 71 positive serum samples and 132 negative serum samples; and the commercial cELISA kit identified 70 positive serum samples and 133 negative serum samples.

[0074] The established cELISA showed concordance rates of 78.33%, 98.52%, 98.03%, and 96.55% with RBT, iELISA, IDVET-iELISA, and keqian-cELISA, respectively. Statistical analysis showed that their kappa values ​​were 0.458, 0.968, 0.957, and 0.924 (Table 8). Therefore, these results indicate that our developed cELISA has high concordance with iELISA and commercial ELISA kits, suggesting that cELISA has significant application potential in clinical testing.

[0075] Table 7 Comparison of cELISA with RBT, iELISA, universal iELISA, and universal cELISA kits

[0076]

[0077] The preferred embodiments of the present invention have been described above, but are not intended to limit the invention. Those skilled in the art can make modifications and variations to the embodiments disclosed herein without departing from the scope and spirit of the invention.

Claims

1. A Brucella lipopolysaccharide monoclonal antibody comprising a heavy chain variable region and a light chain variable region, characterized in that, The amino acid sequence of the heavy chain variable region is SEQ ID No. 1, and the corresponding nucleotide sequence is SEQ ID No. 2; the amino acid sequence of the light chain variable region is SEQ ID No. 3, and the corresponding nucleotide sequence is SEQ ID No.

4.

2. A detection kit containing the Brucella lipopolysaccharide monoclonal antibody of claim 2.

3. The detection kit of claim 1, wherein the kit is a cELISA detection kit.

4. The cELISA detection kit of claim 3, wherein the kit comprises the following: coated antigen: Brucella lipopolysaccharide; detection antibody: horseradish peroxidase-labeled Brucella lipopolysaccharide monoclonal antibody of claim 1; reaction buffer: carbonate buffer, PBST washing solution, skim milk blocking solution; color developing system: TMB substrate solution and H2SO4 stop solution; control: Brucella positive serum and healthy animal serum.

5. Use of the kit of claims 2-4 in detecting Brucella.

6. The use of claim 5, wherein the detection is used to distinguish Brucella and rough Brucella, Yersinia O:9, Dublin Salmonella, Escherichia coli O157:H7, Brucella BP26 protein and / or Mycobacterium tuberculosis IFN-γ.

7. A method for detecting Brucella antibody, using the kit according to claim 4, characterized in that The method comprises the following steps: (1) coating: Brucella lipopolysaccharide is used to coat an enzyme-labeled plate; (2) blocking: skim milk is used for blocking; (3) reaction: the serum to be detected is diluted by 1:10, mixed with an equal volume of 1:100 diluted horseradish peroxidase-labeled Brucella lipopolysaccharide monoclonal antibody of claim 1, and incubated; (4) color development and termination: TMB substrate is added for color development in the dark, and H2SO4 is used to terminate the reaction; (5) result determination: calculate the inhibition rate PI = (OD negative control-OD sample) / OD negative control x 100%, and PI ≥ 29.94% is determined as positive.

8. The detection method of claim 7, wherein: The critical value of the inhibition rate 29.94% is determined by ROC curve (AUC = 0.9952), and the detection limit is 1:25600 serum dilution.